Scholarlink

Background <p>Bladder cancer (BC) ranks as the most prevalent malignant neoplasm affecting the urinary system. However, its clinical prevention and treatment continue to face significant challenges. This research aims to investigate the biological roles and regulatory mechanisms of FRMD6-AS2 in BC.</p> Methods <p>Tissue samples were collected from 132 BC patients, along with their matched adjacent normal tissues. Quantitative reverse transcription polymerase chain reaction was employed to determine FRMD6-AS2 and miR-1260a expression, and their correlation was assessed using Pearson correlation analysis. The link between FRMD6-AS2 and patient prognosis was analyzed via Kaplan-Meier and Cox regression analyses to identify independent prognostic factors. Cell proliferation, migration, invasion, and apoptosis were determined by employing the cell counting kit-8, Transwell, and Annexin V-fluorescein isothiocyanate/ propidium iodide assays. The direct binding interaction between FRMD6-AS2 and miR-1260a was verified by luciferase reporter and RNA immunoprecipitation assays.</p> Results <p>FRMD6-AS2 was lowly expressed in BC tissues and cells. Patients with low FRMD6-AS2 expression exhibited poorer overall survival, and it was identified as an independent prognostic factor. Overexpression of FRMD6-AS2 led to the inhibition of BC cell proliferation, migration, and invasion while promoting apoptosis. Mechanistically, FRMD6-AS2 negatively regulated miR-1260a expression. Furthermore, overexpression of miR-1260a partially reversed the suppressive impacts of FRMD6-AS2 on the malignant behaviors of BC cells.</p> Conclusion <p>FRMD6-AS2 exhibits reduced expression in BC and plays tumor-suppressive effects by sponging miR-1260a, suggesting its potential as a prognostic biomarker and therapeutic target for BC.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

LncRNA FRMD6-AS2 inhibits the malignant progression of bladder cancer by targeting miR-1260a

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2026年1月7日

查看全文
  • Peng Dai,
  • Luchang Chen,
  • Zheng Dong,
  • Hailong Wang,
  • Yong Wen

摘要

Background

Bladder cancer (BC) ranks as the most prevalent malignant neoplasm affecting the urinary system. However, its clinical prevention and treatment continue to face significant challenges. This research aims to investigate the biological roles and regulatory mechanisms of FRMD6-AS2 in BC.

Methods

Tissue samples were collected from 132 BC patients, along with their matched adjacent normal tissues. Quantitative reverse transcription polymerase chain reaction was employed to determine FRMD6-AS2 and miR-1260a expression, and their correlation was assessed using Pearson correlation analysis. The link between FRMD6-AS2 and patient prognosis was analyzed via Kaplan-Meier and Cox regression analyses to identify independent prognostic factors. Cell proliferation, migration, invasion, and apoptosis were determined by employing the cell counting kit-8, Transwell, and Annexin V-fluorescein isothiocyanate/ propidium iodide assays. The direct binding interaction between FRMD6-AS2 and miR-1260a was verified by luciferase reporter and RNA immunoprecipitation assays.

Results

FRMD6-AS2 was lowly expressed in BC tissues and cells. Patients with low FRMD6-AS2 expression exhibited poorer overall survival, and it was identified as an independent prognostic factor. Overexpression of FRMD6-AS2 led to the inhibition of BC cell proliferation, migration, and invasion while promoting apoptosis. Mechanistically, FRMD6-AS2 negatively regulated miR-1260a expression. Furthermore, overexpression of miR-1260a partially reversed the suppressive impacts of FRMD6-AS2 on the malignant behaviors of BC cells.

Conclusion

FRMD6-AS2 exhibits reduced expression in BC and plays tumor-suppressive effects by sponging miR-1260a, suggesting its potential as a prognostic biomarker and therapeutic target for BC.